Critical Survey: Chromadex (CDXC) & FitLife Brands (FTLF)

Chromadex (NASDAQ:CDXC) and FitLife Brands (OTCMKTS:FTLF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Chromadex and FitLife Brands, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chromadex 0 0 1 0 3.00
FitLife Brands 0 0 0 0 N/A

Chromadex currently has a consensus target price of $8.00, suggesting a potential upside of 125.35%. Given Chromadex’s higher possible upside, equities research analysts clearly believe Chromadex is more favorable than FitLife Brands.

Insider and Institutional Ownership

16.6% of Chromadex shares are owned by institutional investors. 10.3% of Chromadex shares are owned by company insiders. Comparatively, 14.5% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Chromadex and FitLife Brands’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chromadex $21.20 million 9.23 -$11.37 million ($0.35) -10.14
FitLife Brands $17.80 million 0.30 -$9.76 million N/A N/A

FitLife Brands has lower revenue, but higher earnings than Chromadex.

Risk & Volatility

Chromadex has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, FitLife Brands has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500.

Profitability

This table compares Chromadex and FitLife Brands’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chromadex -112.99% -77.80% -61.86%
FitLife Brands -45.49% -124.35% -25.62%

Summary

Chromadex beats FitLife Brands on 7 of the 11 factors compared between the two stocks.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People's Republic of China. ChromaDex Corporation is based in Irvine, California.

FitLife Brands Company Profile

FitLife Brands, Inc. manufactures and markets nutritional supplements for health conscious consumers in the United States and internationally. The company offers weight loss, general health, and sports nutrition supplements, such as Censor, Cardio Cuts, and LipoRUSH DS; precision sports nutrition formulations for professional muscular development, including Amplify XL, Pump Fuel, and Flex Stack; weight loss and sports nutrition performance enhancing supplements for fitness enthusiasts comprising Isolate, Ultrakarbs, and NeuroLean; and men's health and weight loss formulations consisting of JXT5 and PyroStim. It also provides diet, health, and sports nutrition supplements and related products that support accelerated fitness and nutrition goals directly to athletic facilities, gyms, and independent retailers; and sports nutritionals, energy and sports drink products, and meal replacements. The company sells and markets its sports, weight loss, and general nutrition products under the NDS Nutrition Products, PMD, SirenLabs, and CoreActive brand names directly to franchise locations. It also markets its men's health and weight loss formulations under the Metis Nutrition brand through corporate and franchise stores; and sports nutritionals, energy and sports drink products, meal replacements, and weight loss products under the iSatori, BioGenetic Laboratories, and Energize brand names through approximately 25,000 retail locations, including specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit